Eurofins Global Central Laboratory expands and relocates its European Kit-Packing facility

Breda, The Netherlands - September, 2011

Eurofins Global Central Laboratory announces that it has relocated its European Kit Packing Facility to a new and larger location to accommodate the increasing volume of clinical trial supply orders. The new 1500 square meter building in Oosterhout is within close proximity to the Eurofins Global Central Laboratory headquarters in Breda. The move is part of the Group’s strategy to optimize and increase efficiency within its laboratory network.

“The new and expanded facility has been designed to efficiently manage the increased demand and future projections of kit requirements for our clinical trials. Expansion to a new and larger facility was inevitable," explains supply chain manager Kristian Leer. “We had full discretion to use a green field approach. This translates into a clear design of the work floor based on the Kit Packing work flow, colour-based zoning to support the processes and an optimized lay-out of our warehousing. The design of the facility is based on the lean principles that create value, efficient flow, and continuous improvement to better meet the needs of our customers.”

With increasing complexity of clinical study protocols, clinical specimen collection kits have also become more complex. As Eurofins Global Central Laboratory offers one of the broadest testing portfolios in the industry, a typical patient visit kit may comprise safety, PK, biomarker, genomic and or microbiology sample collection supplies. When designing the specimen collection kits required for any clinical study protocol, Eurofins Global Central Laboratory is dedicated to supporting Investigator sites to increase their operational efficiency. Eurofins supplies optimally-designed, easy to use, intuitive visit-specific specimen collection and transportation kits that incorporate all relevant materials and forms for handling and shipping to Eurofins Global Central Laboratory for analysis.

René van Erp, Managing Director, explains: "This expansion and redesign of our Kit Packing facility is a direct result of our commitment to improve our customer experience, while addressing such critical business needs as improving efficiencies, broadening capacity to meet demand, and increasing our competitiveness in the market place."

About Eurofins Global Central Laboratory
Eurofins operates one of the industry’s leading central laboratories worldwide, supporting clinical trials in more than 50 countries across six continents. Eurofins Global Central Laboratory is fully dedicated to providing standardized, high quality global central laboratory services to support all phases of clinical trials. With over 20 years of experience and scientific accomplishment, the laboratory testing portfolio has become one of the widest available in the pharmaceutical industry and offers the synergy of integrating all laboratory services. Eurofins Global Central Laboratory supports its customers with wholly owned and harmonized facilities in the United States, Europe, India, Singapore, and China to continually attain the most cost effective and efficient solutions for your clinical trial needs.

For further information please contact:
Eurofins Global Central Laboratory
Email: clinicaltrials@eurofins.com

Investor Relations and Corporate Communications
Phone: +32-2-769 7383
E-mail: ir@eurofins.com

Notes for the editor:
Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With over 9,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 40,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.

The Eurofins Group is the world leader in food testing and one of the global market leaders in pharmaceuticals and environmental testing. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods. As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.